author-photo

Carlos Enrique Vigil

Vanderbilt University

4

Papers

6

Citations

Citation Trend

Filter By

Papers (3) Sort By

Journal Conference Others

The Combination of AXL Inhibitor Bemcentinib and Low Dose Cytarabine Is Well Tolerated and Efficacious in Elderly Relapsed AML Patients: Update from the Ongoing BGBC003 Phase II Trial (NCT02488408)

2020 Blood
Show All
- Source
- Cite
- Save
Citations (0)
First-in class selective AXL inhibitor bemcentinib (BGB324) in combination with LDAC or decitabine exerts anti-leukaemic activity in AML patients unfit for intensive chemotherapy: Phase II open-label study.

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (3)
The immunomodulatory activity of bemcentinib (BGB324): A first-in-class selective oral AXL inhibitor in patients with relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome.

2018 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (2)